Speaker Profile
DO, Chief Medical Officer, Inst. for Neurodegenerative Disorders
Biography
Dr. Tropea graduated from Tufts University and University of New England College of Osteopathic Medicine. He completed his residency in Neurology at NY Presbyterian Hospital-Weill Cornell Medical College and Memorial Sloan-Kettering, where he served as chief resident. He completed fellowship and research post-doc in movement disorders at the University of Pennsylvania studying biomarkers of cognitive impairment in Parkinson’s disease. He is the Chief Medical Officer at the Institute for Neurodegenerative Disorders and works on the Parksinson Precision Medicine Initiative. He is also an Adjunct Assistant Professor of Neurology at the University of Pennsylvania Perelman School of Medicine where he sees patients with Parkinson’s disease and other movement disorders. His research focuses on biomarkers and genetics in neurodegenerative diseases in the development of precision medicine approaches for Parkinson’s disease and other neurodegenerative diseases.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
David Liebeskind, UCLA
PMWC Award Ceremony
• Li-Huei Tsai, MIT Picower Institute (Pioneer)
• Thomas C. Südhof, Stanford (Nobel Laureate, Pioneer)
• David Holtzman, WashU (Pioneer)
• Henrik Zetterberg, UCL / Gothenburg (Luminary)
Featured Speakers
• Thomas C. Südhof, Stanford
• Li-Huei Tsai, MIT Picower Institute
• David Holtzman, WashU
• Henrik Zetterberg, UCL / Gothenburg
• Mark Mintun, Lilly
• Randall Bateman, WashU
• Nikolaos Mellios, Circular Genomics
• Robert Rissman, USC
• Lynn Kramer, Eisai
• Thomas F. Tropea, University of Pennsylvania
• Ari J. Green, UCSF
• Diane Chan, Mass General Brigham
• Leslie Shaw, University of Pennsylvania
• Prashanthi Vemuri, Mayo Clinic
• Kejal Kantarci, Mayo Clinic
• Dan Huddleston, Lightbox Science
• Patrick Brannelly, 10K Brains
• Allan Levey, Emory
From Blood Test to Treatment
Are we finally diagnosing Alzheimer's early enough to change care?
Precision Diagnostics Across Neurology
From biomarker to bedside across neurological disease.
Neurodegeneration Beyond Alzheimer's
Parkinson's, ALS, and FTD in the precision era.
AI & Imaging Across Neurological Disease
Precision phenotyping in stroke, epilepsy, and neurodegeneration.
Why Precision Neurology Is Not Scaling
The evidence, infrastructure, access, and workflow barriers that must be fixed.
Harnessing Brain Rhythms
Gamma oscillations, brain circuits, and the future of neurotherapy.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
